Compare Asana Inc. (ASAN) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Illumina, Inc. — how do they compare? Asana Inc. trades at $7.42 (market cap $1.69B), while Illumina, Inc. trades at $188.25 (market cap $28.78B). The key difference: Illumina, Inc. is far larger — about 17× Asana Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | ILMN | |
|---|---|---|
Market Cap | $1.69B | $28.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.35 | $194.33 |
52-Week Low | $5.46 | $91.00 |
Enterprise Value | $1.51B | $30.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $7.33, down 0.54% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $378M in 2022 to $724M in 2025, though net losses persist. Recent Q1 2027 earnings beat expectations at $0.10 per share, and strategic acquisitions like StackAI enhance AI capabilities. Analyst consensus is mixed with 42% buy ratings and a $9.86 price target, representing 35% upside from current levels.
The outlook balances growth potential against profitability challenges. Positive catalysts include FedRAMP authorization for government contracts and AI innovation, but risks stem from intense competition with Microsoft and decelerating revenue growth. Cash flow turned positive in 2025, yet negative margins and high valuation multiples require careful monitoring for sustained improvement.
Illumina (ILMN) trades at $190.20, down 1.84% on the day but up significantly year-to-date with strong momentum. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reflect a turnaround with net income reaching $850 million in 2025 after previous losses. Recent news highlights product launches and leadership appointments, with the company scheduled to report Q2 2026 earnings on July 30, 2026.
The outlook remains positive with analyst consensus leaning bullish, though valuation multiples appear elevated. Key risks include competitive pressure from new entrants like Roche's Axelios sequencer and execution challenges in maintaining profitability growth. The upcoming earnings report will be critical for validating the current rally's sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
